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Abstract
 Background—Recent studies demonstrated low-grade inflammation in patients with Irritable 
Bowel Syndrome (IBS). However, these studies have been relatively small and do not enable 
examination of this factor in different subtypes of IBS and the possibility of confounding effects of 
co-morbidities that may be associated with inflammatory responses.
 Goals—To investigate the association between high sensitive C - reactive protein (hs-CRP) and 
the diagnosis of IBS, IBS-subtypes, symptoms' severity and IBS-associated co-morbidities.
 Study—This cross-sectional study uses data from a large matched case control study of IBS 
subjects and healthy controls (HC). hs-CRP levels were measured in all subjects. IBS diagnosis 
was determined by Rome III criteria, negative screening blood tests and normal colonoscopy. 
Subjects were evaluated for IBS severity and associated pain and psychological co-morbidities
 Results—A total of 242 IBS patients and 244 HC were studied. Median hs-CRP levels in the 
IBS group were significantly higher than in HC (1.80, IQR 0.7-4.04 mg/l vs 1.20, IQR 
0.5-2.97mg/l respectively, p<0.006,). Levels were highest in IBS-D patients with greater disease 
severity. Hs-CRP levels mildly correlated with symptoms severity (r=0.169, p=0.009); this 
correlation was stronger for the IBS-D patients (r=0.27, p=0.006). IBS was a significant 
independent predictor (p=0.025) for higher hs-CRP levels, whereas other pain and psychological 
co-morbidities were not.
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 Conclusions—Given these observations of cross-sectional differences in hs-CRP between 
IBS subtypes and severity, independent of pain and co-morbidities, more research is needed to 
explore a possible role of low-grade inflammation in the pathogenesis and/or clinical presentation 
of IBS.
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 INTRODUTCION
Irritable bowel syndrome (IBS) is a common disorder with a global prevalence of 8-23% of 
the adult population 1 and is slightly more prevalent in the industrialized world than in 
developing countries. The pathophysiology of IBS is not well understood. It is traditionally 
considered a multifactorial disorder associated with impaired brain-gut function, altered 
intestinal motility and visceral hypersensitivity 2. Although IBS is not considered an 
inflammatory disease, recent studies suggest a possible role for alterations in the intestinal 
immune function and low grade inflammation in its pathogenesis 3-5. The first evidence for 
an inflammatory component in IBS was reported in 1960 showing that IBS patients have a 
higher number of mast cells in their intestinal wall compared to healthy subjects 6. More 
recent studies have described additional histopathologic abnormalities in biopsies from the 
intestinal mucosa of patients with IBS, including increased numbers of activated 
immunocompetent cells, such as: intraepithelial lymphocytes, lamina propria CD3+ cells, 
CD25+ cells, neutrophils and mast cells compared with controls 7, 8.
Additional support for a potential role for low-grade inflammation in IBS came from 
epidemiological observational studies showing that in 6-17% of IBS patients the onset of 
symptoms may relate to an acute episode of gastrointestinal infection; usually referred to as 
“post-infectious IBS” (PI-IBS) 9, 10. Of particular interest are the findings of ongoing 
alterations in enteroendocrine cells, higher number of T-cell lymphocytes 11 and increased 
expression of interleukin 1β in mucosal biopsies of patients with PI-IBS 12. Other studies 
that investigated systemic immune function in patients with IBS have demonstrated that an 
underlying inflammatory response can also be identified in peripheral blood. Examples are 
genetic studies demonstrating reduced levels of IL-10 expression, findings of increased ratio 
of pro- to anti-inflammatory cytokines (i.e., IL-10 to IL-12) 13, increased release of pro-
inflammatory cytokines (e.g., IL-1β_, IL-6, and TNF-α) from peripheral blood mononuclear 
cells (PBMCs) 14 and increased numbers of activated T cells in the peripheral blood 15 in 
patients with IBS compared to controls. In a recent case control study 16 we investigated the 
possibility of detectible systemic inflammatory response in IBS by comparing the levels of 
high-sensitive C-reactive protein (hs-CRP), a non-specific marker of inflammation, in 
patients with IBS and healthy controls (HC). We found a significantly higher levels of hs-
CRP in patients with IBS (n=88, 1.17±1.26 mg/dl) compared to HC (n=352, 0.72mg/dl; 
p<0.001). However, that previous study did not have a sufficient statistical power to enable 
comparisons between the clinical subtypes of IBS and to investigate the possible 
confounding effect of co-morbidities commonly reported with IBS, which could be related 
to elevated hs-CRP.
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The aim of the current study was to investigate the association between hs-CRP and IBS, 
IBS subtypes, IBS symptoms severity, the presence of other pain syndromes (e.g., 
fibromyalgia, migraine headache) and psychological co-morbidities (e.g. depression, 
anxiety, somatization) in a large well defined cohort of patients with IBS. We hypothesized 
that hs-CRP levels in subjects with IBS: (1) are higher compared to HC, (2) vary between 
the IBS clinical subtypes, (3) are positively correlated with IBS symptoms severity, and (4) 
are not explained by other commonly reported co-morbidities.
 MATERIAL AND METHODS
 Study design
This cross-sectional study uses data collected as part of a large matched case control study 
of IBS subjects and HC conducted at the University of North Carolina at Chapel Hill (UNC-
CH) during 2007-2009. Subjects were recruited by advertisement from the general 
population and the UNC-CH outpatient clinics. All subjects were evaluated at a single study 
visit at which a clinical exam was performed, questionnaires were administered, and blood 
samples were obtained. The study protocol was approved by the UNC-CH Institutional 
Review Board and subjects signed an informed consent form prior to enrollment in the 
study.
 Study population
All study participants were 18 years old or older. IBS was diagnosed by an experienced 
physician based on Rome III criteria and negative screening blood tests. All IBS patients 
must have had IBS symptoms for 6 or more months and a normal colonoscopy or barium 
enema during the previous 12 months to rule out organic or obstructive disease. Subjects 
with any history of the following were excluded: evidence of a structural abnormality of the 
digestive tract, inflammatory bowel disease (IBD), intestinal resection, GI malignancy, 
microscopic colitis, celiac sprue, or within six months, any history of ileus, symptomatic 
cholelithiasis, pancreatitis, abdominal adhesions and/or stricture with evidence of small 
bowel obstruction, recurrent diverticulitis or unexplained rectal bleeding (including a 
positive fecal occult blood test (FOBT)).
HC were assessed by a study physician using ROME III criteria and were found negative for 
IBS at the time of enrollment. Persons were excluded if they had any history of IBS 
diagnosis in themselves or any first degree relatives, had been referred to a GI specialist for 
GI abdominal pain, had any history of functional constipation, infectious hepatitis B or C, 
HIV, celiac disease, and gastro-oesophageal reflux disease (GERD). If any had obtained 
screening colonoscopy or barium enema with prior 12 months, results must have been 
normal.
 Measurements and evaluations
All participants underwent a detailed medical history and completed previously validated 
questionnaires. IBS diagnosis and its clinically relevant subtype were determined using the 
ROME III criteria for IBS 17. IBS severity was assessed using the Functional Bowel 
Disorders Symptom Severity Index (FBDSI)18. Somatic and psychological comorbidities 
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were assessed using the Patient Health Questionnaire comprised of 15 somatic symptoms 
(PHQ-15) 19 and Hospital Anxiety and depression scale (HADS) 20. Other co-morbid pain 
syndromes (TMJ syndrome - Temporomandibular joint syndrome, migraine headache, 
fibromyalgia, chronic fatigue and pelvic pain) were assessed by self-report. All subjects 
provided blood samples for routine laboratory tests and serum hs- CRP.
 Statistics
Continuous variables were summarized using the mean and standard deviation (SD) for 
normally distributed variables, or the median (IQR) for non-normally distributed variables; 
categorical variables were summarized using frequency distributions.
Using data from our prior study of 16, we determined that a minimum sample size of 77 in 
each group would be needed to detect a difference in hs-CRP levels of 0.5 mg/liter between 
patients and HD (β=0.2, α=0.05), assuming a SD of 1.26 and 0.91 in each group; for a 
difference of 0.4 mg/l, 120 per group would be needed.
Since hs-CRP has a non-normal distribution, all hs-CRP results in tables and figures are 
shown as median and IQR. For correlations and multivariable modeling, log-transformed hs-
CRP values were used.
Independent t-test and chi square statistics were used for comparisons between cases and HC 
for socioeconomic and demographic variables, psychological characteristics and health 
status. Mann-whitney test was used to compare hs-CRP levels between IBS and HC, and 
Kruskal-Wallis tests to compare hs-CRP levels between clinical sub-types of IBS and 
between severity subgroups of IBS. Further investigation of the association between hs-CRP 
and IBS severity was done using Spearman correlation coefficients. We conducted two 
Mann-whitney tests for each stratum of co-morbidity, and multiple linear regression models 
to assess whether the higher hs-CRP levels in IBS patients were explained by co-morbid 
conditions.
For all analyses, we used a two-tailed significance test of p<0.05 to determine a statistical 
significance. The SPSS statistical package (Version 15, SSPS Inc., Chicago, IL), was used 
for all analyses.
 RESULTS
 1) Study population characteristics
A total of 486 participants (242 IBS patients and 244 HC) were included in the analysis after 
excluding 18 patients (8 IBS and 10 HC) with abnormally elevated (≥ 35 mg/l) hs-CRP 
(n=2), missing hs-CRP levels (n=21), withdrawn consent, not meeting ROME III criteria for 
IBS, or diagnoses of other GI disease.
There were no differences between IBS patients and HC for sex, age or BMI. All 
participants were of Caucasian ethnicity. IBS patients were significantly less educated, and 
had lower income compared to HC (Table 1).
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Most (41.7%; n=101) of the IBS group were classified as either diarrhea-predominant (IBS 
D) or unspecified subtype (36.8%; n=89), with smaller numbers of constipation-
predominant (IBS-C) (16.1%; n=39), and mixed (IBS-M) subtypes (5.4%; n=13).
Most IBS patients scored mild on symptom severity (52.5%; n=126), followed by moderate 
(36.3%, n=87) and severe (11.3%; n=27) by FBDSI.
A significant higher percentage of IBS patients suffered from depression and anxiety and 
had more somatic symptoms (Table 1).
The prevalence of pain syndromes was significantly higher in the IBS group. The most 
prevalent syndromes were migraine headache (35.1%) followed by TMJ syndrome (25.2%), 
fibromyalgia (14.9%), pelvic pain (12.4%) and chronic fatigue (7.0%). Moreover, the 
prevalence of all other non-pain co-morbid conditions was significantly higher in the IBS 
group with a borderline significance for cystitis (Table 1).
 2) Associations of hs-CRP with IBS diagnosis and IBS-subtypes
The median hs-CRP level was significantly higher in the IBS group compared with the HC 
(1.80, IQR 0.7-4.04 mg/l vs 1.20, IQR 0.5-2.97 mg/l, p<0.006) (Figure 1).
Among IBS patients in the highest severity subgroup, median hs-CRP was significantly 
higher in IBS-D patients than IBS-C (4.98, IQR 2.22-8.96 vs. 1.10, IQR 0.55-2.6 mg/l 
respectively, p=0.0025) (Figure 2). However, this relationship was not observed among the 
mild and moderate severity subgroups, where median levels of hs-CRP were similar between 
IBS-D and IBS-C subtypes (Figure 3). Median hs-CRP levels increased with mild, 
moderate, and severe symptom severity (Figure 3) but only among persons with IBS-D 
subtype (1.7, 2.34, 4.98 respectively, p=.045).
 3) Association of hs-CRP with symptoms severity
Hs-CRP level correlated with symptom severity of IBS (r=0.169 p=0.009), and this 
correlation was stronger among IBS-D patients (r=0.27, p=0.006). Symptoms severity also 
correlated with depression, anxiety and somatization (r=0.203, p=0.002; r=0.235, p=0.000; 
r=0.259, p=0.000, respectively)
 4) Association of hs-CRP with IBS and co-morbid conditions
We used stratified analyses to adjust for possible inflammation associated with co-morbid 
pain and psychological syndromes, comparing hs-CRP levels between the IBS group and 
HC within strata defined by presence of pain and/or psychological (depression, anxiety and 
somatization) syndromes. In all strata, hs-CRP levels were consistently higher in the IBS 
group compared with the HC. For pain syndrome-defined strata, hs-CRP was 36-46% higher 
(Figure 4) in IBS patients (2.29, vs. 1.68 mg/l, p=0.18 and 1.61 vs. 1.10 mg/l, p=0.07, with 
and without pain syndrome, respectively).
Similar differences were observed within psychological syndrome strata: IBS versus HC hs-
CRP levels were 1.90 vs. 0.58 mg/l (p=0.067), and 1.77 vs. 1.20 mg/l (p=0.043) in 
participants with and without psychological co-morbidities, respectively. This relationship of 
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higher hs-CRP in IBS patients remained within strata defined by both pain and 
psychological syndromes (any pain or psychological co-morbidity, versus neither) 1.81 vs 
1.20 mg/l in the co-morbid stratum (p=0.042) , and 1.32 vs 1.06 mg/l in the stratum without 
co-morbidities (p=0.460).
In order to test whether the higher hs-CRP levels in subjects with IBS are explained by other 
commonly reported co-morbidities, we created a multivariate linear model, designed to 
identify which, if any, co-morbid variables significantly predicted hs-CRP levels. In this 
model IBS was found to be a significant (p=0.025) predictor for hs-CRP whereas pain 
syndromes and psychological co-morbidities were not. Moreover, when adjusted to age, 
gender, pain syndromes (fibromyalgia, pelvic pain, migraine and chronic fatigue ) and 
psychological co-morbidities (somatization) factors that affect hs-CRP - hs-CRP levels were 
higher by 33% (95% CI 1.05-1.68) among IBS patient compare to HC.
 DISCUSSION
Several lines of data implicate a possible pathomechanistic role for alterations in the 
intestinal immune function and low grade inflammation in some patients with IBS 3-5, 21. 
Genetic studies have demonstrated genetic polymorphisms in TNF-α 22, 23, IL-2 24, IL-4 24, 
IL-6 22, and IL-10 24, 25 in patients with IBS 4. Several studies have shown ongoing 
inflammatory changes (e.g., increased IL-1β expression 12 and lymphocytes infiltration 26) 
in the mucosa of patients with PIIBS and other studies have demonstrated increased 
infiltration of inflammatory cells (e.g., mast cell 27, and T lymphocytes 28) in the intestinal 
mucosa of patient with IBS, not related to PI-IBS.
However, it is recognized that inflammatory processes at the intestinal mucosal level are not 
always reflected in peripheral blood. Indeed, the data documenting systemic inflammatory 
responses in peripheral blood in patients with IBS is much more limited. Pullis et al 29 have 
reported a significantly higher hs-CRP levels in patients with IBS-D (n=117, 1.435 mg/l) 
compare to patients with IBS-C (n=42, 0.383 mg/l; p<0.0001) . However this study did not 
compare these levels to HC. In a recent case control study 16 we found that the levels of hs-
CRP were significantly higher in patients with IBS (n=88, 1.17±1.26 mg/dl) compared to 
HC (n=352, 0.72mg/dl; p<0.001), although these values were within the normal range (0-5 
mg/l). We also found a correlation between hs-CRP levels and IBS severity, however, this 
correlation was observed only among men and we could not demonstrate a similar 
correlation among women. Although these findings suggest a detectible systemic 
inflammatory response in IBS our previous study had several limitations. First, due to the 
small sample size we were not able to investigate and compare the levels of hs-CRP between 
the clinically relevant subtypes of IBS. Thus, although it is reasonable to hypothesize that 
inflammatory responses are associated with specific subtypes of IBS (e.g., IBS-D; as 
suggested by Pullis et al 29) we were not able to provide information on this issue. Second, 
due to limitations of the dataset used in our previous study, we could not investigate possible 
confounding effects of commonly reported co-morbidities that can be associated with 
elevated hs-CRP such as fibromyalgia, migraine headache, pelvic pain, and TMJ syndrome. 
Third, our previous results may not be generalizable to the general population of clinic 
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patients with various chronic diseases given that patients with chronic diseases and CRP 
higher than 10 mg/dl were excluded.
Using data from a large study which was carried out at UNC we were able to confirm our 
previous findings of higher hs-CRP serum levels in IBS patients compared to HC 16, 29. In 
the current study hs-CRP levels were higher in both IBS and HC groups compared to our 
previous study. However, as in our previous study, the hs-CRP levels in both groups were 
within the normal range of 0-5 mg/dl. It should be noted that 36 out of 244 HC and 53 out of 
242 IBS patients had hs-CRP levels above 5 mg/dl suggesting a possible slightly higher 
prevalence of low grade inflammation in a subgroup of patients with IBS compared to HC. 
The differences in hs-CRP levels between the two studies could be due to disparity in the 
exclusion criteria: in the previous study we excluded subjects with CRP levels>10 mg/dl 30 
and those having inflammatory conditions which may affect CRP levels, whereas in the 
current study we used a cut-off hs-CRP level of 35 mg/dl in order to extend the 
generalization of our results.
The larger dataset in this study also enabled us to investigate and compare hs-CRP levels in 
different subgroups of patients based on symptoms severity and bowel characteristics. As 
hypothesized, and consistent with Pullis et al study, the highest hs-CRP levels were found in 
the subgroup of patients with IBS-D (Figure 3).
In addition, we were able to demonstrate, for the first time, that hs-CRP levels correlate with 
symptoms severity of IBS suggesting that IBS, and specifically IBS-D, may be associated 
with systemic inflammatory responses. However, as evident by the correlation analysis the 
association between hs-CRP and symptoms severity are significant although relatively weak, 
both in the general IBS population (r=0.169 p=0.009) and in IBS-D patients (r=0.27, 
p=0.006). These weak correlations can be partially explained by differences in the 
distribution of symptom severity in our study population, as most IBS patients reported mild 
symptom severity (n=126, 52.5%), followed by moderate (n=87, 36.3%) and only a minority 
(n=27, 11.3%) had severe symptom severity. Alternatively, these findings can suggest that 
systemic inflammation is not a prominent phenomenon in IBS or that hs-CRP in peripheral 
blood is not a sensitive marker to detect possible mucosal inflammatory responses in these 
patients.
As mentioned above, the majority of IBS patients in our study suffered from a mild disease 
severity, which represent the general IBS population 18. Moreover, the higher percentage of 
women 1, 31, and the age range (18-81 years) with most subjects younger than 45 years, are 
typical of IBS populations as previously reported 32. In addition, the clinical subtype 
distribution, IBS-D being the most common (41.7%), followed by IBS-C (16.1%) and IBS-
M (5.4%), is also typical of IBS 33.
With regard to psychological and pain co-morbidities, as expected we found that a 
significantly higher percentage of IBS patients suffered from psychological disorders (e.g., 
depression, anxiety and somatization) and had more pain syndromes (e.g., pelvic pain, 
fibromyalgia, migraine, chronic fatigue and TMJ syndrome) and other co-morbid conditions 
compared to HC (Table 1). These findings are in agreement with previous studies34-36. 
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Using a multivariate model, we found that IBS significantly predicted higher hs-CRP levels, 
whereas co-morbidities including psychological disorders and pain syndromes were not. 
This, together with the finding of similar difference in hs-CRP levels (higher by 0.5-0.6 
mg/l, 36-46%) in IBS cases compared to controls and within strata of presence of co-
morbidities, suggest that the differences in hs-CRP levels between cases and controls are 
independent of the commonly reported co-morbidities in IBS.
Moreover, we found that hs-CRP levels among IBS patients are higher by 33% (95% CI 
1.05-1.68) in a multivariate linear model after adjustments for multiple factors that might 
affect CRP. This finding confirms the crude association shown in Figure 1.
Our study has several strengths. The IBS status was rigorously defined by validated 
questionnaires, physician diagnosis, laboratory screening blood tests and recant normal 
colonoscopy/barium enema. The large population size allowed for adequately powered 
comparisons between the different clinical subtypes of IBS and according to severity levels. 
The instruments used to measure possible confounders enabled adjustment for other factors 
known to affect CRP levels such as psychological disorders 37 and additional pain 
syndromes 38. Another strength is the similarity of age, BMI, ethnicity and gender (variables 
known to affect CRP level) between the IBS and HC by groups.
In addition, over one-third of IBS patients (89 patients, 36.8%) did not meet any of the 
subtype's definition, due to the meticulous definition of ROME III, and therefore they were 
classified as “unspecified subtype”, and were not included in the analysis. This should have 
reduced possible misclassification bias due to differing bowel syndromes
A limitation of our study is the use of inflammatory markers measured in peripheral blood 
which may not fully reflect inflammatory processes and immune responses at the level of the 
intestinal mucosa, leading to possible mischaracterization of outcomes. An additional 
potential limitation is the substantial variability between the patients within groups. Thus, 
while medians are significantly different, the individual values would not provide much 
discriminant ability to diagnose IBS or rule it out.
In addition, while we had 242 total IBS patients, we only had 153 subtyped IBS patients due 
to the strict definition of ROME III for IBS subtypes. Once these 153 patients are further 
divided into 3 subtypes of IBS-D (n=101), IBS-C (n=39), and IBS-M (n=13), power is 
limited, especially for IBS-M subtype. Thus, comparisons of hs-CRP stratified by severity 
were performed between IBS-D vs. IBS-C.
In conclusion, the results of our study support the hypothesis that intestinal inflammation 
may play a role in the pathogenesis of symptoms in a subgroup of patients with IBS. Our 
findings suggest that inflammatory responses in IBS may be identified in peripheral blood, 
specifically in IBS-D patients with severe symptoms. Our study underline the need for 
further investigation to identify additional sensitive inflammatory biomarkers for IBS and to 
determine whether inflammatory biomarkers can contribute to the diagnosis, direct specific 
treatment or serve as potential markers of response to therapy.
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ESR Erythrocyte sedimentation rate
FOBT Fecal occult blood test
GERD Gastrooesophageal reflux disease
GI Gastrointestinal
HC Healthy controls
Hs-CRP High-sensivite C-Reactive protein
IBD Inflammatory bowel disease
IBS Irritable bowel syndrome
IBS-C Constipation-predominant irritable bowel syndrome
IBS-D Diarrhea-predominant irritable bowel syndrome
IBS-M Mix irritable bowel syndrome
IBS-U Unspecified irritable bowel syndrome
TMJ syndrome Temporomandibular joint syndrome
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Figure 1. hs-CRP levels in IBS vs. HC
Median hs-CRP (mg L−1) level higher in the IBS group compared with the HC (1.80, IQR 
0.7-4.04 mg/l vs 1.20, IQR 0.5-2.97 mg/l, p<0.006)
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Figure 2. hs-CRP levels in subtypes of IBS with severe symptoms
Median hs-CRP (mg L−1) levels in two subtypes of IBS having severe symptoms. hs-CRP 
was higher in IBS-D than IBS-C (4.98, IQR 2.22-8.96, IQR 0.74-5.18 mg/l, vs. 1.10, IQR 
0.55-2.6 mg/l respectively, p=0.0025).
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Figure 3. hs-CRP levels in clinical subtypes of IBS patients by symptom severity
Median hs-CRP (mg L−1) levels by IBS subtypes and severity levels. Among IBS-D group, 
hs-CRP levels increased with mild-moderate-severe symptom severity, ( 1.70, IQR 0.56-4.00 
mg/l, vs. 2.34, IQR 0.88-4.26 mg/l , vs. 4.98, IQR 2.22-8.96 mg/l, respectively, p=0.0045).
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Figure 4. hs-CRP levels in IBS vs. HC by morbidity
Median hs-CRP (mg L−1) levels in IBS vs. HC in both strata: presence or absence of any 
pain syndrome. Meian hs-CRP levels was higher in IBS group compared with the HC in 
both strata (2.29, IQR 0.78-4.49 mg/l vs. 1.68, IQR 0.6-3.8mg/l, p=0.18 in patients with pain 
syndrome, and 1.61 IQR 0.67-3.95 mg/l vs. 1.10, IQR 0.5-2.7 mg/l, p=0.07 in patients 
without a pain syndrome, respectively).
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Table 1
Comparison of demographic and socioeconomic characteristics, psychological profile, pain syndromes and co-
morbid conditions between IBS patients and controls
IBS (242) HC (244) p value1
Demographic characteristics
Sex - % Women (n) 79.8% (193) 79.5% (194) N.S.
Age (mean±S.D.) (years) 38.78±14.16 39.87±15.04 N.S.
BMI (mean±S.D.) (kg/m2) 26.93±6.55 25.97±5.95 N.S.
Socioeconomic status
Education - % more than 15 years (n) 64.0% (155) 74.6% (182) 0.042
Family income – % >100,000$per year (n) 16.7% (40) 28.3% (68) 0.006
Psychological health profile
Depression - % (n) 9.6% (23) 0.4% (1) 0.000
Anxiety – % (n) 25.0% (60) 6.1% (15) 0.000
Somatization - % (n) 82.2% (199) 58.6% (143) 0.000
Prevalence of pain syndromes
Migraine - % (n) 35.1% (85) 14.3% (35) 0.000
Fibromyalgia – % (n) 14.9% (36) 0.8% (2) 0.000
Chronic fatigue - % (n) 7.0% (17) 0.4% (1) 0.000
Pelvic pain - % (n) 12.4% (30) 5.3% (13) 0.007
TMJ syndrome - % (n) 25.2% (60) 10.7% (26) 0.000
Prevalence of co-morbid conditions
Hay fever - % (n) 36.4% (88) 25.8% (63) 0.014
Asthma - % (n) 19.4% (47) 12.7% (31) 0.048
Drug allergy - % (n) 50.0% (121) 29.5% (72) 0.000
Lactose intolerance - % (n) 13.6% (33) 4.1% (10) 0.000
Prevalence of co-morbid conditions
Functional dyspepsia - % (n) 2.1% (5) 0.0% (0) 0.030
GERD - % (n) 28.1% (68) 5.7% (14) 0.000
Cystitis - % (n) 5.4% (13) 2.0% (5) 0.058
N.S. – Non significant
HC – Healthy controls
IBS - Irritable bowel syndrome
TMJ syndrome - Temporomandibular joint syndrome
GERD –Gastro-esophageal reflux disease
1Chi square for categorical variables and t-test for continuous variables
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